Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
20.00K | 426.00K | -68.00K | 4.41M | 8.19M | Gross Profit |
20.00K | -51.00K | -136.00K | 3.86M | -25.32M | EBIT |
-103.17M | -95.93M | -87.74M | -96.91M | -54.80M | EBITDA |
-94.81M | -87.94M | -84.40M | -96.53M | -54.15M | Net Income Common Stockholders |
-95.06M | -88.45M | -84.71M | -96.17M | -49.04M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
131.89M | 197.81M | 184.88M | 190.30M | 215.92M | Total Assets |
139.31M | 210.64M | 206.93M | 218.86M | 245.12M | Total Debt |
1.68M | 671.00K | 1.12M | 1.54M | 1.82M | Net Debt |
-35.24M | -134.45M | -109.97M | -188.77M | -114.09M | Total Liabilities |
15.80M | 16.54M | 21.64M | 19.73M | 19.24M | Stockholders Equity |
123.51M | 194.10M | 185.29M | 199.13M | 225.88M |
Cash Flow | Free Cash Flow | |||
-79.85M | -75.86M | -62.71M | -90.55M | -34.78M | Operating Cash Flow |
-79.85M | -75.81M | -62.59M | -78.24M | -34.44M | Investing Cash Flow |
-28.39M | 13.73M | -73.40M | 87.52M | -72.09M | Financing Cash Flow |
10.04M | 86.11M | 56.78M | 65.10M | 213.49M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
66 Neutral | $490.83M | 12.24 | 20.50% | ― | 2333.50% | ― | |
52 Neutral | $5.04B | 3.15 | -44.58% | 2.85% | 16.08% | -0.27% | |
52 Neutral | $462.31M | ― | -57.28% | ― | -95.12% | 21.09% | |
50 Neutral | $488.85M | ― | 344.74% | ― | -47.32% | -26.67% | |
45 Neutral | $324.69M | ― | -49.97% | ― | -14.16% | 25.80% | |
43 Neutral | $345.84M | ― | -48.45% | ― | ― | 7.15% | |
33 Underperform | $401.49M | ― | -71.44% | ― | ― | 19.94% |
On May 13, 2025, Altimmune entered into a Loan and Security Agreement with Hercules Capital, securing a $100 million credit facility to enhance its financial flexibility and support the development of its lead therapeutic candidate, pemvidutide. The company announced its first quarter 2025 financial results, reporting cash and short-term investments of $150 million as of March 31, 2025. Altimmune anticipates significant milestones in 2025, including top-line data from the IMPACT Phase 2b trial of pemvidutide in MASH, and the initiation of Phase 2 trials for AUD and ALD. These developments are expected to strengthen Altimmune’s position in the biopharmaceutical industry, particularly in addressing unmet medical needs in liver and cardiometabolic diseases.
The most recent analyst rating on (ALT) stock is a Buy with a $24.00 price target. To see the full list of analyst forecasts on Altimmune stock, see the ALT Stock Forecast page.
Spark’s Take on ALT Stock
According to Spark, TipRanks’ AI Analyst, ALT is a Neutral.
Altimmune’s strong balance sheet and promising clinical pipeline are positive, but challenges remain with profitability and cash flow. Technical indicators are neutral, while the earnings call provides some optimism for future growth.
To see Spark’s full report on ALT stock, click here.
Altimmune announced its financial results for the fourth quarter and full year of 2024, highlighting significant progress in the development of pemvidutide. The company completed enrollment for the Phase 2b IMPACT trial in MASH and expects to report top-line data in Q2 2025. Additionally, Altimmune received FDA clearance for investigational new drug applications in two more indications, with Phase 2 trials slated for mid-2025. The company also strengthened its board with two new pharmaceutical industry veterans and plans to host a virtual R&D Day on March 13, 2025, to discuss further developments.
On February 24, 2025, Altimmune, Inc. expanded its Board of Directors by appointing Teri Lawver and Jerome Durso, both seasoned executives in the biopharmaceutical industry. This strategic move comes as the company progresses into late-stage clinical development of pemvidutide, a promising treatment for liver and metabolic diseases. Lawver and Durso bring extensive experience in commercialization and corporate strategy, which is expected to bolster Altimmune’s efforts in transitioning to a pre-commercial-stage organization and advancing its strategic vision.